Press Release
CEL-SCI Corporation (NYSE AMEX: CVM) announced today that it has received and responded to a Warning Letter issued to the Company by the Division of Drug Advertising Marketing and Compliance (DDMAC) U.S. Food and Drug Administration (FDA) regarding certain statements made about the Company s investigational therapy Multikine (Leukocyte Interleukin, Injection)* on its corporate website.